This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (59)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biederman, J.
Right arrow Articles by Chandler, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biederman, J.
Right arrow Articles by Chandler, M. C.
Related Collections
Right arrow Neurology & Psychiatry
PEDIATRICS Vol. 110 No. 2 August 2002, pp. 258-266

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SLI381 (Adderall XR) in Children With Attention-Deficit/Hyperactivity Disorder

Joseph Biederman, MD*, Frank A. Lopez, MD{ddagger}, Samuel W. Boellner, MD§ and Mark C. Chandler, MD||

* Massachusetts General Hospital, Boston, Massachusetts
{ddagger} Children’s Developmental Center, Maitland, Florida
§ Clinical Study Centers, Little Rock, Arkansas
|| North Carolina Neuropsychiatry, Chapel Hill, North Carolina on behalf of the SLI381.301 Study Group

Objective. SLI381 (Adderall XR) is a 2-component extended-release capsule formulation of Adderall designed to produce a therapeutic effect that lasts throughout the day with 1 morning dose. The primary objective of this study was to assess the efficacy and safety of SLI381 compared with placebo in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children in a naturalistic school and home setting. A secondary objective was to assess the diurnal variation in responses based on morning and afternoon assessments.

Methods. A multicenter, randomized, double-blind, parallel-group, placebo-controlled trial was conducted at 47 sites. After a 1-week washout of any previous stimulant medication, patients were randomized to receive single-daily morning doses of placebo or SLI381 10 mg, 20 mg, or 30 mg for 3 weeks. Participants aged 6 to 12 years inclusive who satisfied Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria diagnosis of ADHD were included. The primary efficacy parameter was the Conners Global Index Scale for Teachers. Secondary efficacy parameters included the Conners Global Index Scale for Parents, the Clinical Global Impressions Scale for improvement, and the Parent Global Assessment for improvement. Safety was assessed by recording adverse events, laboratory tests, and vital signs at each visit during the study. Physical examinations and electrocardiograms were performed at the screening and the end of the study.

Results. Five hundred eighty-four children were randomized, 563 were included in the intent-to-treat population, and 509 completed the entire study. Intention-to-treat analysis of Conners Global Index Scale for Teachers and Conners Global Index Scale for Parents scores revealed significant improvement in morning, afternoon, and late afternoon behavior for all active treatment groups versus placebo. All active treatment groups showed significant dose-related improvement in behavior from baseline. Both the Clinical Global Impressions Scale for improvement and Parent Global Assessment for improvement showed all doses of SLI381 to be superior to placebo at treatment end and both confirmed the dose-response relationship between improvement and the SLI381 dose. The incidence of spontaneously reported adverse events was low and similar for active treatments and placebo.

Conclusions. SLI381 produced consistent, dose-related improvements on all measures of efficacy. The extended-release nature of the SLI381 formulation was shown by continued, significant improvement in afternoon assessments by teachers and afternoon and late afternoon assessments by parents. The time course and therapeutic effects of SLI381 suggests that this medication is an efficacious once-daily treatment for children with ADHD.

Key Words: attention-deficit/hyperactivity disorder • amphetamine • Adderall XR • randomized • controlled trial

Abbreviations: ADHD, attention-deficit/hyperactivity disorder • ECG, electrocardiogram • DISC, Diagnostic Interview Schedule for Children • CGIS-T, Conners Global Index Scale for Teachers • CGIS-P, Conners Global Index Scale for Parents • CGI, Clinical Global Impressions Scale for improvement • PGA, Parent Global Assessment for Improvement • ITT, intention-to-treat • ANCOVA, analysis of covariance

Received for publication Jul 11, 2001; Accepted Feb 20, 2002.




This article has been cited by other articles:


Home page
 CirculationHome page
V. L. Vetter, J. Elia, C. Erickson, S. Berger, N. Blum, K. Uzark, and C. L. Webb
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Circulation, May 6, 2008; 117(18): 2407 - 2423.
[Full Text] [PDF]

Home page
 J Atten DisordHome page
S. V. Faraone, S. B. Wigal, and P. Hodgkins
Forecasting Three-Month Outcomes in a Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR) and Atomoxetine (Strattera) in School-Aged Children With ADHD
J Atten Disord, July 1, 2007; 11(1): 74 - 82.
[Abstract] [PDF]

Home page
 PediatricsHome page
T. E. Wilens, J. B. Prince, T. J. Spencer, and J. Biederman
Stimulants and Sudden Death: What Is a Physician to Do?
Pediatrics, September 1, 2006; 118(3): 1215 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
T. E. Wilens, K. McBurnett, O. Bukstein, J. McGough, L. Greenhill, M. Lerner, M. A. Stein, C. K. Conners, J. Duby, J. Newcorn, et al.
Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder
Arch Pediatr Adolesc Med, January 1, 2006; 160(1): 82 - 90.
[Abstract] [Full Text] [PDF]

Home page
 J Atten DisordHome page
S. B. Wigal, J. J. McGough, J. T. McCracken, J. Biederman, T. J. Spencer, K. L. Posner, T. L. Wigal, S. H. Kollins, T. M. Clark, D. A. Mays, et al.
A Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR(R)) and Atomoxetine (Strattera(R)) in School-Aged Children With Attention Deficit/Hyperactivity Disorder
J Atten Disord, August 1, 2005; 9(1): 275 - 289.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
S. V. Faraone, T. J. Spencer, C. B. Montano, and J. Biederman
Attention-Deficit/Hyperactivity Disorder in Adults: A Survey of Current Practice in Psychiatry and Primary Care
Arch Intern Med, June 14, 2004; 164(11): 1221 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. Biederman, S. V. Faraone, M. C. Monuteaux, and J. R. Grossbard
How Informative Are Parent Reports of Attention-Deficit/Hyperactivity Disorder Symptoms for Assessing Outcome in Clinical Trials of Long-Acting Treatments? A Pooled Analysis of Parents' and Teachers' Reports
Pediatrics, June 1, 2004; 113(6): 1667 - 1671.
[Abstract] [Full Text] [PDF]